
NRSN Stock Forecast & Price Target
NRSN Analyst Ratings
Bulls say
NeuroSense Therapeutics is a promising biotechnology company due to its leading product candidate, PrimeC, a novel extended-release, oral formulation for neurodegenerative diseases. The company has made significant strides in improving its regulatory and clinical positioning, with a potential NOC/c pathway submission and upcoming data readouts for Alzheimer's disease. However, investors may remain focused on the company's near-term capital needs, which may require additional financing to fund late-stage development. Nevertheless, the recent JAMA publication and additional data presentations have further strengthened the company's credibility and potential for partnerships and regulatory alignment in the future. With a strong focus on multiple indications and mechanisms, NeuroSense is poised for success through key catalysts in the coming years.
Bears say
NeuroSense Therapeutics is making progress with its product candidate, PrimeC, and has received FDA clearance for its Phase 3 program and published positive data. However, the company's year-end cash position is concerning and leaves financing risk as the most pressing issue. Despite the potential for PrimeC as a differentiated neurodegenerative treatment, the company's tight balance sheet could hinder its future success.
This aggregate rating is based on analysts' research of NeuroSense Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.
NRSN Analyst Forecast & Price Prediction
Start investing in NRSN
Order type
Buy in
Order amount
Est. shares
0 shares